Login to Your Account



Higher Dose Phase II Trial in the Works

Oxford's Parkinson's Gene Therapy Improves Symptoms

By Nuala Moran
BioWorld International Corresponden

Wednesday, December 21, 2011
LONDON – Oxford BioMedica plc can now boast three years' safety data and a sustained improvement in symptoms in all 15 patients treated in the Phase I/II trial of its ProSavin gene therapy for Parkinson's disease, but needs to progress to a higher dose "to provide more certainty" that this is not just a placebo effect, and to be competitive against deep brain stimulation treatment.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription